Literature DB >> 7437246

Repeated investigations of cyclophosphamide disposition in myeloma patients receiving intermittent chemotherapy.

G Edwards, R T Calvert, D Crowther, V Bramwell, H Scarffe.   

Abstract

1 The disposition of cyclophosphamide was investigated in a group of myeloma patients. 2 Marked changes in clearance and volume of distribution of cyclophosphamide occurred between investigations. 3 The observed changes in disposition did not correlate with biochemical estimates of renal and hepatic function or plasma protein status.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7437246      PMCID： PMC1430067          DOI： 10.1111/j.1365-2125.1980.tb01756.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  11 in total

1.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  Cyclophosphamide, vincristine and sequential split-course radiotherapy in the treatment of small cell lung cancer.

Authors:  P Y Holoye; M L Samuels
Journal:  Chest       Date:  1975-06       Impact factor: 9.410

3.  Enzymatic basis of cyclophosphamide activation by hepatic microsomes of the rat.

Authors:  J L Cohen; J Y Jao
Journal:  J Pharmacol Exp Ther       Date:  1970-08       Impact factor: 4.030

4.  Statistical estimations in pharmacokinetics.

Authors:  H G Boxenbaum; S Riegelman; R M Elashoff
Journal:  J Pharmacokinet Biopharm       Date:  1974-04

5.  Quantitative GLC determination of cyclophosphamide and isophosphamide in biological specimens.

Authors:  C Pantarotto; A Bossi; G Belvedere; A Martini; M G Donelli; A Frigerio
Journal:  J Pharm Sci       Date:  1974-10       Impact factor: 3.534

6.  Clinical pharmacology of cyclophosphamide.

Authors:  C M Bagley; F W Bostick; V T DeVita
Journal:  Cancer Res       Date:  1973-02       Impact factor: 12.701

7.  The effect of phenobarbital or 2-diethylaminoethyl-2,2-diphenylvalerate on the activation of cyclophosphamide in vivo.

Authors:  R B Field; M Gang; I Kline; J M Venditti; V S Waravdekar
Journal:  J Pharmacol Exp Ther       Date:  1972-02       Impact factor: 4.030

Review 8.  The serum level approach to individualization of drug dosage.

Authors:  J Koch-Weser
Journal:  Eur J Clin Pharmacol       Date:  1975-10-10       Impact factor: 2.953

Review 9.  Renal failure, drug pharmacokinetics and drug action.

Authors:  J Fabre; L Balant
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

10.  The effect of phenobarbital on cyclophosphamide antitumor activity.

Authors:  D S Alberts; T van Daalen Wetters
Journal:  Cancer Res       Date:  1976-08       Impact factor: 12.701
View more
  5 in total

Review 1.  Pharmacokinetic drug interactions of commonly used anticancer drugs.

Authors:  F M Balis
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

2.  Pharmacokinetics and metabolism of cyclophosphamide in paediatric patients.

Authors:  M J Tasso; A V Boddy; L Price; R A Wyllie; A D Pearson; J R Idle
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 3.  Clinical pharmacokinetics of cyclophosphamide.

Authors:  M J Moore
Journal:  Clin Pharmacokinet       Date:  1991-03       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of cyclophosphamide.

Authors:  Milly E de Jonge; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

5.  Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients.

Authors:  Nuala Helsby; Minghan Yong; Kathryn Burns; Michael Findlay; David Porter
Journal:  Cancer Chemother Pharmacol       Date:  2021-06-10       Impact factor: 3.333
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.